Glenmark Pharma US Arm to Launch Sodium Phosphate Injection, Distribution Begins April

• Glenmark Pharmaceuticals Ltd.'s US subsidiary is launching sodium phosphates injection USP in various single-dose vials.
• The single-dose vial is bioequivalent and therapeutically equivalent to Hospira Inc.'s reference listed drug.
• Glenmark will commence distribution of the injection in April 2026.
• The injection's single-dose vials market recorded annual sales of approximately $66.8 million for the 12 months ending December 2025.
• Glenmark expects core business margins to expand by 100-150 basis points in FY27 and aims to be debt-free by March.